巨星醫療控股(02393.HK)建議境外債務重組
格隆匯7月20日丨巨星醫療控股(02393.HK)公吿,於2016年9月15日,公司已發行2億美元到期日為2021年9月15日的6.9%優先票據。票據於聯交所上市,股份代號為4508。
於2020年,由於Covid-19疫情爆發,集團經歷了艱辛的一年。於2020年上半年,大部分醫院資源已預留對抗Covid-19,令到體外診斷設備安裝試劑及相關耗材的需求大跌。因此,集團於2020年的收益及溢利較2019年有所下跌。於過去數月,公司與其不同債權人及相關顧問進行建設性對話,通力為集團的債務重組達成協定。
為促進與所有票據持有人的全面公開溝通,以及以有效公平的方式處理集團的現有資金流動性問題,公司謹此宣佈有關票據的建議重組計劃。
公司認為,儘早完成建議重組符合其全體持份者的利益。公司相信此舉將讓集團改善資本架構,將專注力重投日常運作,藉此改善現金流及流動性,同時提高持份者價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.